Condyloma acuminatum is a common lesion of the penis and genitalia. It uncommonly involves the urethra but when it does the lesions are difficult to eradicate. Treatment has included excision, fiuguration, podophyline and thiotepa0 none of which has been entirely successful. We report a case of intraurethral condyloma acuminatum treated with thiotepa instillation in 27 years old male patient
Adult ; Genitalia ; Humans ; Male ; Penis ; Thiotepa* ; Urethra

A series of 135 cases of pterygium observed at the Eye Dept. in the National Medical Center from April 1963 to May 1966, were treated with thio-tepa after the surgical removal and were studied clinically in regard to the incidence of the recurrence. Among the total series, only one case showed no response to the thio-tepa instillation and the recurrence persisted. There was a case of allergic response to the thio-tepa, which has not been found in any reports known. No serious local or systemic toxcity or any sequelae such as corneal damages, defective vision or the interference with wound healing could be observed.
Incidence ; Korea* ; Pterygium ; Recurrence ; Thiotepa ; Wound Healing

Study group consists of 30 cases whose follow-up period is over 6 months among 32 cases of bladder tumors treated with thio-TEPA instillation following TUR during the period from January, 1978 through June, 1981. Control group consists of 25 cases whose follow-up period is over 6 months among 33 cases of bladder tumors treated by TUR only during the period from January, 1971 through December, 1977. Following results were obtained: 1. Recurrence rate: In study group, 30% In control group, 64% 2. Interval between TUR & the first recurrence: In study group, average 8.1 months In control group, average 7.1 months 3. Number of tumors at first recurrence: In study group: 89%: under 2 11%: over 3 In control group: 25%: under 2 75%: over 3
Follow-Up Studies ; Recurrence ; Thiotepa* ; Urinary Bladder Neoplasms* ; Urinary Bladder*

Clinical observation was male on 20 cases of bladder tumors treated by thio-TEPA instillations fo1lowing TUR during the period from January, 1978 through September, 1979 and the following results were obtained. Among 20 cases of bladder tumor. 1) 7cases have been followed up without recurrence. 2) 4 cages have been followed up without recurrence with instillations, who had previous recurrences following T.U.R. only. 3) 4 cases recurred in spite of 4 thio-TEPA instillations. 4) 5 cases were not followed up sufficiently.
Humans ; Male ; Recurrence ; Thiotepa* ; Urinary Bladder Neoplasms* ; Urinary Bladder*

Local instillation of Thio-tepa (triethylene thiophosphoramide) is widely used as an important adjunct in the management of papilloma of the bladder. We herein report the 10 case of the bladder cancer administered with Thio-tepa for the treatment and prophylaxis.
Administration, Intravesical* ; Papilloma ; Thiotepa* ; Urinary Bladder Neoplasms* ; Urinary Bladder*

Intravesical thio-tepa instillations for 25 patients with superficial bladder tumors were evaluated postoperatively to reconfirm its usefulness as a prophylactic agent. The over-all recurrence rate to prophylactic thio-tepa was 28%, with minor toxicity observed in 32% of the Cases. Thio-tepa Can be given safely in the postoperative period and is effective in decreasing the recurrence rate and prolonging interval free of disease of superficial bladder tumors.
Humans ; Postoperative Period ; Recurrence ; Thiotepa* ; Urinary Bladder Neoplasms* ; Urinary Bladder*

Intravesical thio-tepa instillations for 25 patients with superficial bladder tumors were evaluated postoperatively to reconfirm its usefulness as a prophylactic agent. The over-all recurrence rate to prophylactic thio-tepa was 28%, with minor toxicity observed in 32% of the Cases. Thio-tepa Can be given safely in the postoperative period and is effective in decreasing the recurrence rate and prolonging interval free of disease of superficial bladder tumors.
Humans ; Postoperative Period ; Recurrence ; Thiotepa* ; Urinary Bladder Neoplasms* ; Urinary Bladder*

The results of cryotherapy for 12 cases with the tendency of recurrent pterygium treated with Thio-tepa or strontium 90 after the surgical removal are presented. There appeared the rupture of vessels. and edema following cryocautery for: 3~15 days. No special complication or any sequelae in the eyeball is observed. The irritatini signs such as foreign body sensation, lacrimation or photophobia are easily relieved with systemic treatment of Celestamin tablet.
Cryotherapy ; Edema ; Foreign Bodies ; Photophobia ; Pterygium* ; Rupture ; Sensation ; Strontium ; Thiotepa

20 cases of study group whose follow-up period is over 6 months among 22 cases of bladder tumors treated with doxorubicin instillation following TUR during the period from December, 1981 through December, 1983 were compared with 30 cases of controlled group whose follow-up period is over 6 months among 32 cases of bladder tumors treated with thio-tepa instillation following TUR during the period from January, 1978 through June, 1981. Following result were obtained. 1. Recurrence rate In TUR + doxorubicin, 25%, In TUR+thio-tepa,30% 2. Interval between TUR & the first recurrence: In TUR + doxorubicin, average 9 months, In TUR + thio-tepa, average 8.1 months 3. Complication: In TUR + doxorubicin, painful urination in 2 cases(10%), In TUR + thio-tepa, hematuria, dysuria, painful urination, and urethral stricture in 8 cases(26.7%).
Doxorubicin* ; Dysuria ; Follow-Up Studies ; Hematuria ; Recurrence ; Thiotepa* ; Urethral Stricture ; Urinary Bladder Neoplasms* ; Urinary Bladder* ; Urination

Primary transitional cell carcinoma of the bladder was treated with prophylactic and therapeutic Intravesical thiotepa in 7 cases. In 5 cases of stage A tumor, postoperative follow up was averaged 10.8 months and 4 cases were tumor free (80%). In 2 cases of infiltrating tumor, the instillation was not effective. Thiotepa can be given safely in the 7 days post-operative period and no leukopenia and bladder irritation symptoms were occurred.
Carcinoma, Transitional Cell ; Follow-Up Studies ; Leukopenia ; Thiotepa* ; Urinary Bladder Neoplasms* ; Urinary Bladder*